Table 1 Patient demographics
Post 1 (n = 171) | Post 2 (n = 327) | Post 3 (n = 162) | ||
|---|---|---|---|---|
Age | 62 [22–86] | 65 [22–89] | 66 [22–89] | P = 0.004 |
Sex | P = 0.858 | |||
Male | 106 (62.0%) | 201 (61.5%) | 96 (59.3%) | |
Female | 65 (38.0%) | 126 (38.5%) | 66 (40.7%) | |
Disease | P = 0.644 | |||
Acute leukaemia/MDS | 2 (1.2%) | 10 (3.1%) | 5 (3.1%) | |
Allograft <1 y | 11 (6.4%) | 11 (3.4%) | 5 (3.1%) | |
Allograft >1 y | 34 (19.9%) | 64 (19.6%) | 29 (17.9%) | |
CLL | 18 (10.5%) | 41 (12.5%) | 19 (11.7%) | |
Lymphoma (B cell) | 22 (12.9%) | 45 (13.8%) | 23 (14.2%) | |
Lymphoma (Hodgkin) | 9 (5.3%) | 9 (2.8%) | 4 (2.5%) | |
Lymphoma (PTLD) | 4 (2.3%) | 3 (0.9%) | 3 (1.9%) | |
MPN (ET) | 24 (14%) | 50 (15.3%) | 32 (19.8%) | |
MPN (Myelofibrosis) | 16 (9.4%) | 28 (8.6%) | 14 (8.6%) | |
MPN (PV) | 11 (6.4%) | 36 (11%) | 19 (11.7%) | |
Plasma Cell Dyscrasia | 15 (8.8%) | 20 (6.1%) | 7 (4.3%) | |
Other (MPN other/Lymphoma other) | 5 (2.9%) | 10 (3.1%) | 2 (1.2%) | |
Treatment | P = 0.781 | |||
BTKi | 10 (5.8%) | 13 (4.0%) | 8 (4.9%) | |
Chemo (<6 m) | 21 (12.3%) | 30 (9.2%) | 11 (6.8%) | |
Hydroxycarbamide | 19 (11.1%) | 53 (16.2%) | 33 (20.4%) | |
Interferon | 7 (4.1%) | 9 (2.8%) | 5 (3.1%) | |
JAKi | 11 (6.4%) | 21 (6.4%) | 11 (6.8%) | |
None | 24 (14.0%) | 59 (18.0%) | 27 (16.7%) | |
PTx-Chemo | 3 (1.8%) | 3 (0.9%) | 1 (0.6%) | |
PTx-Immunosuppression | 19 (11.1%) | 27 (8.3%) | 17 (10.5%) | |
PTx-Off Immunosuppression | 17 (9.9%) | 32 (9.8%) | 10 (6.2%) | |
PTx-TKI | 5 (2.9%) | 11 (3.4%) | 6 (3.7%) | |
R/O-Chemo (<6 m) | 18 (10.5%) | 37 (11.3%) | 20 (12.3%) | |
R/O-Chemo (6–24 m) | 5 (2.9%) | 5 (1.5%) | 2 (1.2%) | |
R/O-Chemo (>24 m) | 4 (2.3%) | 11 (3.4%) | 5 (3.1%) | |
Venetoclax | 1 (0.6%) | 9 (2.8%) | 4 (2.5%) | |
Other | 7 (4.1%) | 7 (2.1%) | 2 (1.2%) | |
Response | ||||
Detectable anti-S | 81 (47.4%) | 239 (73.1%) | 140 (86.4%) | P < 0.001 |
Anti-S titre >568 BAU/ml | 3 (1.8%) | 63 (19.3%) | 95 (58.6%) | P < 0.001 |
